Dmitry Balyasny’s Adaptimmune Therapeutics ADAP Stock Holding History

Dmitry Balyasny’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-259,413	Closed	-$1.34M	–	2179
2021 Q3	$1.34M	Buy	+259,413	New	+$1.16M	0.01%	1257
2019 Q1	–	Sell	-567,401	Closed	-$3.26M	–	1371
2018 Q4	$3.26M	Sell	567,401 -414,599	-42%	-$3.06M	0.02%	591
2018 Q3	$13.3M	Buy	982,000 +165,716	+20%	+$1.74M	0.06%	402
2018 Q2	$9.69M	Sell	816,284 -130,784	-14%	-$1.63M	0.04%	498
2018 Q1	$10.6M	Buy	947,068 +224,078	+31%	+$1.96M	0.04%	506
2017 Q4	$4.83M	Buy	722,990 +123,190	+21%	+$951K	0.02%	874
2017 Q3	$4.91M	Buy	599,800 +411,313	+218%	+$2.57M	0.02%	730
2017 Q2	$846K	Buy	+188,487	New	+$985K	﹤0.01%	1148

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dmitry Balyasny's ADAP Position: Q4 2021 in Review

Dmitry Balyasny sold out of Adaptimmune Therapeutics (ADAP) in Q4 2021, closing a stake of 259,413 shares — an estimated $1.34M sold.

Dmitry Balyasny first reported a position in ADAP in Q2 2017 and held it in 8 quarters. The position peaked at $13.3M in Q3 2018. 85 funds tracked by Wall St. Rank hold ADAP as of Q4 2021.

Dmitry Balyasny reported no remaining Adaptimmune Therapeutics position as of Q4 2021 after selling out during the quarter.
Dmitry Balyasny sold 259,413 Adaptimmune Therapeutics shares in Q4 2021, an estimated $1.34M.
Dmitry Balyasny first reported a position in Adaptimmune Therapeutics in Q2 2017 and held it in 8 quarters.
Dmitry Balyasny's Adaptimmune Therapeutics position peaked at $13.3M in Q3 2018.
85 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2021.

Based on Balyasny Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.